亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Stereotactic Body Radiation Therapy for Lung Metastases From Sarcoma in Oligometastatic Patients: A Phase 2 Study

医学 转移瘤切除术 临床终点 放射治疗 肉瘤 临床研究阶段 前瞻性队列研究 放射外科 转移 放射科 外科 核医学 化疗 内科学 癌症 随机对照试验 病理
作者
Pierina Navarria,Davide Baldaccini,Elena Clerici,Beatrice Marini,Luca Cozzi,Davide Franceschini,Alexia Bertuzzi,Vittorio Quagliuolo,Valter Torri,Piergiuseppe Colombo,Ciro Franzese,Luisa Bellu,Marta Scorsetti
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier BV]
卷期号:114 (4): 762-770 被引量:33
标识
DOI:10.1016/j.ijrobp.2022.08.028
摘要

Purpose

The lung is the most frequent site of metastasis in patients with sarcoma. Pulmonary metastasectomy is the most common treatment performed. Stereotactic body radiation therapy (SBRT) has proven to be a potential alternative to resection. This prospective phase 2 study aimed to assess the role of SBRT for patients with lung metastases.

Methods and Materials

Adult patients with up to 4 lung metastases (LMs) ≤5 cm in diameter and unsuitable for surgery were included. Dose prescription was based on site and size: 30 Gy/1 fraction for peripheral lesions ≤10 mm, 60 Gy/3 fractions for peripheral lesions 11 to 20 mm, 48 Gy/4 fractions for peripheral lesions >20 mm, and 60 Gy/8 fractions for central lesions. The primary endpoint was the proportion of treated lesions free from progression at 12 months. Secondary endpoints were disease-free survival (DFS), overall survival (OS), and toxicity.

Results

Between March 2015 and December 2020, 44 patients with a total of 71 LMs were enrolled. Twelve-month local control was 98.5% ± 1.4%, reaching the primary aim; the median DFS time was 12 months (95% CI, 8-16 months), and the 1-, 2-, 3-, 4-, and 5-year PFS rates were 50% ± 7.5%, 19.5% ± 6.6%, 11.7% ± 5.8%, 11.7% ± 5.8%, and 11.7% ± 5.8%, respectively. The median OS time was 49 months (95% CI, 24-49 months), and the 1-, 2-, 3-, 4-, and 5-year OS rates were 88.6% ± 4.7%, 66.7 ± 7.6%, 56.8% ± 8.4%, 53.0% ± 8.6%, and 48.2% ± 9.1%, respectively. Prognostic factors recorded as significantly affecting survival were age, grade of primary sarcoma, interval time from diagnosis to occurrence of LMs, and number of LMs. No severe pulmonary toxicity (grade 3-4) occurred.

Conclusions

The study found a local control of LMs in almost all patients treated, with negligible toxicity. Survival was also highly satisfactory. Well-designed randomized trials comparing surgery with SBRT for patients with metastatic lung sarcoma are needed to confirm these preliminary data.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小巧惜蕊完成签到,获得积分10
18秒前
jcksonzhj完成签到,获得积分10
1分钟前
阳光灭绝完成签到,获得积分10
1分钟前
魔术师完成签到,获得积分10
2分钟前
2分钟前
Tsing驳回了Akim应助
2分钟前
完美飞凤完成签到,获得积分10
2分钟前
2分钟前
陆上飞完成签到,获得积分10
3分钟前
3分钟前
安静成仁完成签到,获得积分10
3分钟前
轻松凌柏完成签到 ,获得积分10
3分钟前
3分钟前
悦耳乘风完成签到,获得积分10
4分钟前
和谐早晨完成签到,获得积分10
5分钟前
dS3mV4bO5vK7mM8n完成签到,获得积分10
5分钟前
幽默的冰之完成签到,获得积分10
5分钟前
感动的易真完成签到,获得积分10
6分钟前
zc完成签到,获得积分10
6分钟前
灵巧笑旋完成签到,获得积分10
7分钟前
合适的飞绿完成签到,获得积分10
7分钟前
欢呼亦绿完成签到,获得积分10
7分钟前
7分钟前
Zhou完成签到,获得积分10
7分钟前
8分钟前
干净的向秋完成签到 ,获得积分10
8分钟前
任性孤菱完成签到 ,获得积分10
8分钟前
彭于晏应助程宇采纳,获得10
8分钟前
可爱的函函应助程宇采纳,获得10
8分钟前
上官若男应助程宇采纳,获得10
8分钟前
SciGPT应助程宇采纳,获得10
8分钟前
bkagyin应助程宇采纳,获得10
8分钟前
Jasper应助程宇采纳,获得10
8分钟前
慕青应助程宇采纳,获得10
8分钟前
深情安青应助程宇采纳,获得10
8分钟前
共享精神应助程宇采纳,获得10
8分钟前
小巧如音完成签到,获得积分10
8分钟前
无限的寡妇完成签到,获得积分10
9分钟前
9分钟前
洁净的向南完成签到 ,获得积分10
9分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
化工安全与环保 1000
Autoparametric Resonance in Mechanical Systems 1000
基于锂离子电池正极材料回收的绿色溶剂开发及工程化应用研究 800
Cosmos as Art Object: Studies in Plato's Timaeus and Other Dialogues 600
Management and the Arts 510
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7651282
求助须知:如何正确求助?哪些是违规求助? 9222621
关于积分的说明 19801937
捐赠科研通 7216598
什么是DOI,文献DOI怎么找? 3278494
关于科研通互助平台的介绍 2439359
邀请新用户注册赠送积分活动 2277223